[1]
|
Sedykh, S.E., Prinz, V.V., Buneva, V.N. and Nevinsky, G.A. (2018) Bispecific Antibodies: Design, Therapy, Perspectives. Drug Design, Development and Therapy, 12, 195-208. https://doi.org/10.2147/DDDT.S151282
|
[2]
|
Ecker, D.M., Jones, S.D. and Levine, H.L. (2015) The Therapeutic Monoclonal Antibody Market. mAbs, 7, 9-14. https://doi.org/10.4161/19420862.2015.989042
|
[3]
|
Sharkey, R.M., Rossi, E.A., Chang, C.H. and Goldenberg, D.M. (2010) Improved Cancer Therapy and Molecular Imaging with Multivalent, Multispecific Antibodies. Cancer Biotherapy & Radiopharmaceuticals, 25, 1-12. https://doi.org/10.1089/cbr.2009.0690
|
[4]
|
Dhimolea E. and Reichert J.M. (2012) World Bispecific Antibody Summit, September 27-28, 2011, Boston, MA. mAbs, 4, 4-13. https://doi.org/10.4161/mabs.4.1.18821
|
[5]
|
Brinkmann, U. and Kontermann, R.E. (2017) The Making of Bispecific Antibodies. mAbs, 9, 182-212. https://doi.org/10.1080/19420862.2016.1268307
|
[6]
|
Zhang, X., Yang, Y., Fan, D. and Xiong, D. (2017) The Development of Bispecific Antibodies and Their Applications in Tumor Immune Escape. Experimental Hematology & Oncology, 6, Article No. 12. https://doi.org/10.1186/s40164-017-0072-7
|
[7]
|
Topp, M.S., Gokbuget, N., Zugmaier, G., Klappers, P., Stelljes, M., Neumann, S., Viardot, A., Marks, R., Diedrich, H., Faul, C., Reichle, A., Horst, H.A., Brüggemann, M., Wessiepe, D., Holland, C., Alekar, S., Mergen, N., Einsele, H., Hoelzer, D. and Bargou, R.C. (2014) Phase II Trial of the anti-CD19 Bispecific T Cell-Engager Blinatumomab Shows Hematologic and Molecular Remissions in Patients with Relapsed or Refractory B-Precursor Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 32, 4134-4140. https://doi.org/10.1200/JCO.2014.56.3247
|
[8]
|
Su, Z., Wang, B., Almo, S.C. and Wu, Y. (2020) Understanding the Targeting Mechanisms of Multi-Specific Biologics in Immunotherapy with Multiscale Modeling. iScience, 23, Article ID: 101835. https://doi.org/10.1016/j.isci.2020.101835
|
[9]
|
Logtenberg, M.E.W., Scheeren, F.A. and Schumacher, T.N. (2020) The CD47-SIRPα Immune Checkpoint. Immunity, 52, 742-752. https://doi.org/10.1016/j.immuni.2020.04.011
|
[10]
|
Lancman, G., Richter, J. and Chari, A. (2020) Bispecifics, Trispecifics, and Other Novel Immune Treatments in Myeloma. Hematology ASH Education Program, 2020, 264-271. https://doi.org/10.1182/hematology.2020000110
|
[11]
|
Huang, L., Shah, K., Barat, B., Lam, C.-Y.K., Gorlatov, S., Ciccarone, V., Tamura, J., Moore, P.A. and Diedrich, G. (2020) Multispecific, Multivalent Antibody-Based Molecules Engineered on the DART® and TRIDENTTM Platforms. Current Protocols in Immunology, 129, e95. https://doi.org/10.1002/cpim.95
|
[12]
|
Gunasekaran, K., Pentony, M., Shen, M., Garrett, L., Forte, C., Woodward, A., Ng, S.B., Born, T., Retter, M., Manchulenko, K., Sweet, H., Foltz, I.N., Wittekind, M. and Yan, W. (2010) Enhancing Antibody Fc Heterodimer Formation through Electrostatic Steering Effects: Applications to Bispecific Molecules and Monovalent IgG. Journal of Biological Chemistry, 285, 19637-19646. https://doi.org/10.1074/jbc.M110.117382
|
[13]
|
Bacac, M., Fauti, T., Sam, J., Colombetti, S., Weinzierl, T., Ouaret, D., Bodmer, W., Lehmann, S., Hofer, T., Hosse, R.J., Moessner, E., Ast, O., Bruenker, P., Grau-Richards, S., Schaller, T., Seidl, A., Gerdes, C., Perro, M., Nicolini, V., Steinhoff, N., Dudal, S., Neumann, S., von Hirschheydt, T., Jaeger, C., Saro, J., Karanikas, V., Klein, C. and Umana, P. (2016) A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors. Clinical Cancer Research, 22, 3286-3297. https://doi.org/10.1158/1078-0432.CCR-15-1696
|
[14]
|
Klein, C., Schaefer, W. and Regula, J.T. (2016) The Use of CrossMAb Technology for the Generation of Bi- and Multispecific Antibodies. mAbs, 8, 1010-1020. https://doi.org/10.1080/19420862.2016.1197457
|
[15]
|
Knodler, M., Korfer, J., Kunzmann, V., Trojan, J., Daum, S., Schenk, M., Kullmann, F., Schroll, S., Behringer, D., Stahl, M., Al-Batran, S.E., Hacker, U., Ibach, S., Lindhofer, H. and Lordick, F. (2018) Randomised Phase II Trial to Investigate Catumaxomab (Anti-EpCAM × Anti-CD3) for Treatment of Peritoneal Carcinomatosis in Patients with Gastric Cancer. British Journal of Cancer, 119, 296-302. https://doi.org/10.1038/s41416-018-0150-6
|
[16]
|
Guo, Q., Zhao, P., Zhang, Z., Zhang, J., Zhang, Z., Hua, Y., Han, B., Li, N., Zhao, X. and Hou, L. (2020) TIM-3 Blockade Combined with Bispecific Antibody MT110 Enhances the Anti-Tumor Effect of γδ T cells. Cancer Immunology, Immunotherapy, 69, 2571-2587. https://doi.org/10.1007/s00262-020-02638-0
|
[17]
|
Hoseini, S.S., Espinosa-Cotton, M., Guo, H.-F. and Cheung, N.-K.V. (2020) Overcoming Leukemia Heterogeneity by Combining T Cell Engaging Bispecific Antibodies. Journal for ImmunoTherapy of Cancer, 8, e001626. https://doi.org/10.1136/jitc-2020-001626
|
[18]
|
Oberst, M.D., Fuhrmann, S., Mulgrew, K., Amann, M., Cheng, L., Lutterbuese, P., Richman, L., Coats, S., Baeuerle, P.A. and Hammond, S.A. (2014) CEA/CD3 Bispecific Antibody MEDI-565/AMG 211 Activation of T Cells and Subsequent Killing of Human Tumors is Independent of Mutations Commonly Found in Colorectal Adenocarcinomas. mAbs, 6, 1571-1584. https://doi.org/10.4161/19420862.2014.975660
|
[19]
|
Al-Hussaini, M., Rettig, M.P., Ritchey, J.K., Karpova, D., Uy, G.L., Eissenberg, L.G., Gao, F., Eades, W.C., Bonvini, E., Chichili, G.R., Moore, P.A., Johnson, S., Collins, L. and DiPersio, J.F. (2016) Targeting CD123 in Acute Myeloid Leukemia Using a T-Cell-Directed Dual-Affinity Retargeting Platform. Blood, 127, 122-131. https://doi.org/10.1182/blood-2014-05-575704
|
[20]
|
Moore, P.A., Shah, K., Yang, Y., Alderson, R., Roberts, P., Long, V., Liu, D., Li, J.C., Burke, S., Ciccarone, V., Li, H., Fieger, C.B., Hooley, J., Easton, A., Licea, M., Gorlatov, S., King, K.L., Young, P., Adami, A., Loo, D., Chichili, G.R., Liu, L., Smith, D.H., Brown, J.G., Chen, F.Z., Koenig, S., Mather, J., Bonvini, E. and Johnson, S. (2018) Development of MGD007, a gpA33 × CD3-Bispecific DART Protein for T-Cell Immuno-therapy of Metastatic Colorectal Cancer. Molecular Cancer Therapeutics, 17, 1761-1772. https://doi.org/10.1158/1535-7163.MCT-17-1086
|
[21]
|
Duell, J., Lukic, D.S., Karg, M., Reusch, U., Koch, J., Zhukovsky, E.A., Rajkovic, E., Treder, M., Rasche, L., Eisele, F., Einsele, H. and Topp, M.S. (2019) Functionally Defective T Cells after Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11. Journal of Immunotherapy, 42, 180-188. https://doi.org/10.1097/CJI.0000000000000267
|
[22]
|
Bartlett, N.L., Herrera, A.F., Domingo-Domenech, E., Mehta, A., Forero-Torres, A., Garcia-Sanz, R., Armand, P., Devata, S., Izquierdo, A.R., Lossos, I.S., Reeder, C., Sher, T., Chen, R., Schwarz, S.E., Alland, L., Strassz, A., Prier, K., Choe-Juliak, C. and Ansell, S.M. (2020) A Phase 1b Study of AFM13 in Combination with Pembrolizumab in Patients with Relapsed or Refractory Hodgkin Lymphoma. Blood, 136, 2401-2409. https://doi.org/10.1182/blood.2019004701
|
[23]
|
Claus, C., Ferrara, C., Xu, W., Sam, J., Lang, S., Uhlenbrock, F., Albrecht, R., Herter, S., Schlenker, R., Hüsser, T., Diggelmann, S., Challier, J., Mossner, E., Hosse, R.J., Hofer, T., Brunker, P., Joseph, C., Benz, J., Ringler, P., Stahlberg, H., Lauer, M., Perro, M., Chen, S., Küttel, C., Mohan, P.L.B., Nicolini, V., Birk, M.C., Ongaro, A., Prince, C., Gianotti, R., Dugan, G., Whitlow, C.T., Solingapuram. S.K.K., Caudell, D.L., Burgos-Rodriguez, A.G., Cline, J.M., Hettich, M., Ceppi, M., Giusti, A.M., Crameri, F., Driessen, W., Morcos, P.N., Freimoser-Grundschober, A., Levitsky, V., Amann, M., Grau-Richards, S., von Hirschheydt, T., Tournaviti, S., Molhoj, M., Fauti, T., Heinzelmann-Schwarz, V., Teichgraber, V., Colombetti, S., Bacac, M., Zippelius, A., Klein, C. and Umana, P. (2019) Tumor-Targeted 4-1BB Agonists for Combination with T Cell Bispecific Antibodies as Off-the-Shelf Therapy. Science Translational Medicine, 11, eaav5989. https://doi.org/10.1126/scitranslmed.aav5989
|
[24]
|
Przepiorka, D., Ko, C.W., Deisseroth, A., Yancey, C.L., Candau-Chacon, R., Chiu, H.-J., Gehrke, B.J., Gomez-Broughton, C., Kane, R.C., Kirshner, S., Mehrotra, N., Ricks, T.K., Schmiel, D., Song, P., Zhao, P., Zhou, Q., Farrell, A.T. and Pazdur, R. (2015) FDA Approval: Blinatumomab. Clinical Cancer Research, 21, 4035-4039. https://doi.org/10.1158/1078-0432.CCR-15-0612
|